“The present situation has exposed some structural weaknesses inside the EU’s medicines offer chain along with a large dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides said. She proposed that provide chain issues be dealt with within an EU pharmaceutical system expected to generally be released by the top on the